-
- Azushima Kengo
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Tamura Kouichi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Wakui Hiromichi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Maeda Akinobu
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Kanaoka Tomohiko
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Ohsawa Masato
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Haku Sona
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Uneda Kazushi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Toya Yoshiyuki
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
-
- Umemura Satoshi
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
Search this article
Abstract
We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 51 (24), 3387-3389, 2012
The Japanese Society of Internal Medicine
